Provided by Tiger Trade Technology Pte. Ltd.

Revolution Medicines, Inc.

203.77
+0.42000.21%
Post-market: 204.610.8425+0.41%17:58 EDT
Volume:1.38M
Turnover:279.15M
Market Cap:43.68B
PE:-22.84
High:206.36
Open:204.98
Low:197.81
Close:203.35
52wk High:224.31
52wk Low:42.18
Shares:214.34M
Float Shares:185.00M
Volume Ratio:1.07
T/O Rate:0.75%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-8.9212
EPS(LYR):-5.9502
ROE:-79.09%
ROA:-30.12%
PB:16.76
PE(LYR):-34.25

Loading ...

Oppenheimer Remains a Buy on Revolution Medicines (RVMD)

TIPRANKS
·
Jun 01

Summit drops as concerns over older patients cloud cancer trial data

Reuters
·
Jun 01

BUZZ-U.S. STOCKS ON THE MOVE -Revolution Medicines, FedEx, Xpeng

Reuters
·
Jun 01

MORNING BID AMERICAS-AI and 1984

Reuters
·
Jun 01

Revolution Medicines Pancreatic Cancer Trial Results Look Solid -- Market Talk

Dow Jones
·
Jun 01

Bellevue flags Merck-Kelun Sac-TMT Phase III OptiTROP-Lung05 data as top ASCO 2026 lung cancer catalyst

Reuters
·
Jun 01

Why doctors stood up and cheered mid-presentation for a historic pancreatic cancer treatment

Dow Jones
·
Jun 01

Stock Track | Revolution Medicines Soars 16.21% in Pre-Market on Breakthrough Pancreatic Cancer Trial Results

Stock Track
·
Jun 01

Movement Alert|Revolution Medicines Rises 15.38% in Pre-Market Trading, ASCO Phase 3 Pancreatic Cancer Data Far Exceeds Expectations

Market Focus
·
Jun 01

Stock Track | Revolution Medicines Soars 17.76% in Night Session on Positive Phase 3 Pancreatic Cancer Trial Results

Stock Track
·
Jun 01

Revolution Medicines' Pancreatic Cancer Pill Doubles Survival, Cuts Death Risk 60% in Trial As Stock Sits Near All-Time Highs

Benzinga
·
Jun 01

Michael Yee Reiterates Buy Rating and Raises Price Target to $175 on Strong Pivotal Data and Launch Prospects for Daraxonrasib in Pancreatic Cancer

TIPRANKS
·
Jun 01

Movement Alert|Revolution Medicines Rises 7.95% Overnight, ASCO Conference RAS Inhibitor Pancreatic Cancer Data Fuels Market Optimism

Market Focus
·
Jun 01

Revolution Medicines announces results from Phase 3 RASolute 302 trial

TIPRANKS
·
Jun 01

Revolution Medicines Announces Asco Plenary Presentation Highlighting Unprecedented Results From Pivotal Phase 3 Rasolute 302 Clinical Trial of Daraxonrasib in Previously Treated Metastatic Pancreatic Cancer

THOMSON REUTERS
·
May 31

CORRECTED-Revolution's pancreatic cancer drug doubles survival, boosts quality of life

Reuters
·
May 31

Revolution Medicines Chief Global Commercialization Officer Anthony Mancini disposes of common shares worth $478,465.61

Reuters
·
May 29

Analysts Conflicted on These Healthcare Names: CVS Health (CVS), Revolution Medicines (RVMD) and Neumora Therapeutics, Inc. (NMRA)

TIPRANKS
·
May 27

What Revolution Medicines (RVMD)'s Phase 3 Daraxonrasib Survival Data Means For Shareholders

Simply Wall St.
·
May 24

Revolution Medicines Initiated at Market Perform by Bernstein

Dow Jones
·
May 22